StockPreacher.com announces investment report featuring ARCA biopharma

Mar 29 2010

StockPreacher.com announces an investment report featuring ARCA biopharma Inc. (Nasdaq:ABIO). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/ABIO

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/StockPreacher

ARCA biopharma Inc. (ABIO) is a biopharmaceutical company whose principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product candidate is Gencaro™ (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator, which is under review by the U.S. Food and Drug Administration for chronic heart failure. ABIO has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. It is collaborating with Laboratory Corp. of America to develop the companion genetic test for Gencaro.

Message Board Search for ABIO: http://www.boardcentral.com/boards/ABIO

In the report, the analyst notes:

"ABIO shares surged last week after the Company announced it received a patent from the U.S. Patent and Trademark Office (USPTO) on methods of treating heart failure patients with bucindolol based on genetic testing. In a news release, ABIO president and CEO Michael R. Bristow stated: 'We are obviously pleased with the USPTO's issuance of this patent which we believe will extend our pharmacogenetic intellectual property protection around bucindolol and, if approved for marketing, provide Gencaro market exclusivity into 2025.'  

"On March 25, 2010, the Company submitted a revised clinical study protocol for review under the FDA's Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of Gencaro in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro ... ABIO currently holds a fast track designation for Gencaro development in Genotype-defined heart failure population."